TAA polyepitope DNA-based vaccines: A potential tool for cancer therapy

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Bei, Roberto ^a   Scardino, Antonio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; ALBINTERFERON ALPHA2B; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; IRINOTECAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MART 1 (26-35) PEPTIDE; MART 1 (27-35) PEPTIDE; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN GP100 209-217; MUCIN 1; PEPTIDE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANDROGEN DEPRIVATION THERAPY; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BILE DUCT CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COLORECTAL CANCER; COMPETITIVE INHIBITION; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DNA TRANSFECTION; DRUG MEGADOSE; EXPRESSION VECTOR; FUSION GENE; HAPLOTYPE; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; METASTASIS; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PERITONEAL CARCINOMA; PERITONEUM CANCER; PROSTATE CARCINOMA; RECOMBINANT PLASMID; REVIEW; TUMOR CELL; TUMOR IMMUNITY; UTERINE TUBE CARCINOMA; ANIMAL; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; VACCINES, DNA;

EID: 77954552963     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/102758     Document Type: Review

References (97)

1. Mou Z., He Y., Wu Y., Immunoproteomics to identify tumor-associated antigens eliciting humoral response Cancer Letters 2009 278 2 123 129
2. Wilcox R., Markovic S. N., Tumor immunotherapy in melanoma: on the dawn of a new era? Current Opinion in Molecular Therapeutics 2007 9 1 70 78
3. Bei R., Masuelli L., Palumbo C., Modesti M., Modesti A., A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth Cancer Letters 2009 281 1 8 23
4. Qiu J., Hanash S., Autoantibody profiling for cancer detection Clinics in Laboratory Medicine 2009 29 1 31 46
5. Houghton A. N., Guevara-Patio J. A., Immune recognition of self in immunity against cancer Journal of Clinical Investigation 2004 114 4 468 471
6. Dranoff G., Targets of protective tumor immunity Annals of the New York Academy of Sciences 2009 1174 74 80
7. Chen X., Chang C.-H., Goldenberg D. M., Novel strategies for improved cancer vaccines Expert Review of Vaccines 2009 8 5 567 576
8. Mocellin S., Pilati P., Nitti D., Peptide-based anticancer vaccines: recent advances and future perspectives Current Medicinal Chemistry 2009 16 36 4779 4796
9. Pilla L., Rivoltini L., Patuzzo R., Marrari A., Valdagni R., Parmiani G., Multipeptide vaccination in cancer patients Expert Opinion on Biological Therapy 2009 9 8 1043 1055
10. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F. M., Anichini A., Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? Journal of the National Cancer Institute 2002 94 11 805 818
11. Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Dudley M. E., Schwarz S. L., Spiess P. J., Wunderlich J. R., Parkhurst M. R., Kawakami Y., Seipp C. A., Einhorn J. H., White D. E., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nature Medicine 1998 4 3 321 327
12. Khazaie K., Bonertz A., Beckhove P., Current developments with peptide-based human tumor vaccines Current Opinion in Oncology 2009 21 6 524 530
13. Cormier J. N., Salgaller M. L., Prevette T., Barracchini K. C., Rivoltini L., Restifo N. P., Rosenberg S. A., Marincola F. M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A Cancer Journal from Scientific American 1997 3 1 37 44
14. Marchand M., van Baren N., Weynants P., Brichard V., Drno B., Tessier M.-H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Linard D., Beauduin M., Dietrich P.-Y., Russo V., Kerger J., Masucci G., Jger E., De Greve J., Atzpodien J., Brasseur F., Coulie P. G., Van Der Bruggen P., Boon T., Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 International Journal of Cancer 1999 80 2 219 230
15. Jger E., Gnjatic S., Nagata Y., Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers 97 Proceedings of the National Academy of Sciences of the United States of America 2000 22 12198 12203
16. Wang F., Bade E., Kuniyoshi C., Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma Clinical Cancer Research 1999 5 10 2756 2765
17. Mittendorf E. A., Gurney J. M., Storrer C. E., Shriver C. D., Ponniah S., Peoples G. E., Vaccination with a HER2/ neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer Surgery 2006 139 3 407 418
18. Disis M. L., Gooley T. A., Rinn K., Davis D., Piepkorn M., Cheever M. A., Knutson K. L., Schiffman K., Generation of T-cell immunity to the HER-2/ neu protein after active immunization with HER-2/ neu peptide-based vaccines Journal of Clinical Oncology 2002 20 11 2624 2632
19. Gjertsen M. K., Buanes T., Rosseland A. R., Bakka A., Gladhaug I., Sreide O., Eriksen J. A., Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma International Journal of Cancer 2001 92 3 441 450
20. Yamamoto K., Ueno T., Kawaoka T., Hazama S., Fukui M., Suehiro Y., Hamanaka Y., Ikematsu Y., Imai K., Oka M., Hinoda Y., MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer Anticancer Research 2005 25 5 3575 3579
21. Ramanathan R. K., Lee K. M., McKolanis J., Hitbold E., Schraut W., Moser A. J., Warnick E., Whiteside T., Osborne J., Kim H., Day R., Troetschel M., Finn O. J., Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer Cancer Immunology, Immunotherapy 2005 54 3 254 264
22. Weihrauch M. R., Arisn S., Jurkiewicz E., Geisen C., Xia Z., Anderson K. S., Gracien E., Schmidt M., Wittig B., Diehl V., Wolf J., Bohlen H., Nadler L. M., Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer Clinical Cancer Research 2005 11 16 5993 6001
23. Ho O., Green W. R., Alternative translational products and cryptic T cell epitopes: expecting the unexpected Journal of Immunology 2006 177 12 8283 8289
24. Houghton A. N., Guevara-Patio J. A., Immune recognition of self in immunity against cancer Journal of Clinical Investigation 2004 114 4 468 471
25. Kyewski B., Klein L., A central role for central tolerance Annual Review of Immunology 2006 24 571 606
26. Hogquist K. A., Baldwin T. A., Jameson S. C., Central tolerance: learning self-control in the thymus Nature Reviews Immunology 2005 5 10 772 782
27. Zaremba S., Barzaga E., Zhu M., Soares N., Tsang K.-Y., Schlom J., Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen Cancer Research 1997 57 20 4570 4577
28. Salazar E., Zaremba S., Arlen P. M., Tsang K. Y., Schlom J., Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide International Journal of Cancer 2000 85 6 829 838
29. Loftus D. J., Squarcina P., Nielsen M.-B., Geisler C., Castelli C., dum N., Appella E., Parmiani G., Rivoltini L., Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART127-35 Cancer Research 1998 58 11 2433 2439
30. Rivoltini L., Squarcina P., Loftus D. J., Castelli C., Tarsini P., Mazzocchi A., Rini F., Viggiano V., Belli F., Parmiani G., A superagonist variant of peptide MART1/melan A27-35 elicits anti- melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy Cancer Research 1999 59 2 301 306
31. Valmori D., Lvy F., Miconnet I., Zajac P., Spagnoli G. C., Rimoldi D., Linard D., Cerundolo V., Cerottini J.-C., Romero P., Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue Journal of Immunology 2000 164 2 1125 1131
32. Hoffmann T. K., Loftus D. J., Nakano K., Maeurer M. J., Chikamatsu K., Appella E., Whiteside T. L., DeLeo A. B., The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53264-272 epitope Journal of Immunology 2002 168 3 1338 1347
33. Vertuani S., Sette A., Sidney J., Southwood S., Fikes J., Keogh E., Lindencrona J. A., Ishioka G., Levitskaya J., Kiessling R., Improved immunogenicity of an immunodominant epitope of the Her-2/nea protooncogene by alterations of MHC contact residues Journal of Immunology 2004 172 6 3501 3508
34. Tourdot S., Scardino A., Saloustrou E., Gross D. A., Pascolo S., Cordopatis P., Lemonnier F. A., Kosmatopoulos K., A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes European Journal of Immunology 2000 30 12 3411 3421
35. Scardino A., Gross D.-A., Alves P., Schultze J. L., Graff-Dubois S., Faure O., Tourdot S., Chouaib S., Nadler L. M., Lemonnier F. A., Vonderheide R. H., Cardoso A. A., Kosmatopoulos K., HER-2/ neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy Journal of Immunology 2002 168 11 5900 5906
36. Hess A. D., Thoburn C. J., Miura Y., Bright E. C., Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen Clinical Immunology 2005 114 3 307 319
37. Hess A. D., Thoburn C., Chen W., Miura Y., Van Der Wall E., The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen Clinical Immunology 2001 101 1 67 76
38. Voutsas I. F., Gritzapis A. D., Mahaira L. G., Salagianni M., Von Hofe E., Kallinteris N. L., Baxevanis C. N., Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/ neu peptide linked to the Ii-Key moiety of the invariant chain International Journal of Cancer 2007 121 9 2031 2041
39. Sotiriadou N. N., Kallinteris N. L., Gritzapis A. D., Voutsas I. F., Papamichail M., Von Hofe E., Humphreys R. E., Pavlis T., Perez S. A., Baxevanis C. N., Ii-Key/HER-2/ neu (776790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/ neu + tumors Cancer Immunology, Immunotherapy 2007 56 5 601 613
40. Holmes J. P., Benavides L. C., Gates J. D., Carmichael M. G., Hueman M. T., Mittendorf E. A., Murray J. L., Amin A., Craig D., Von Hofe E., Ponniah S., Peoples G. E., Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER-2/ neu peptide (AE37) vaccine Journal of Clinical Oncology 2008 26 20 3426 3433
41. Kallinteris N. L., Lu X., Wu S., Hu H., Li Y., Gulfo J. V., Humphreys R. E., Xu M., Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV Vaccine 2003 21 27-30 4128 4132
42. Gritzapis A. D., Mahaira L. G., Perez S. A., Cacoullos N. T., Papamichail M., Baxevanis C. N., Vaccination with human HER-2/ neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/ neu /-expressing tumor cells in vivo Cancer Research 2006 66 10 5452 5460
43. Dionne S. O., Myers C. E., Smith M. H., Lake D. F., Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction Cancer Immunology, Immunotherapy 2004 53 4 307 314
44. Kobayashi H., Wood M., Song Y., Appella E., Celis E., Defining promiscuous MHC class II helper T-cell epitopes for the HER2/ neu tumor antigen Cancer Research 2000 60 18 5228 5236
45. Feyerabend S., Stevanovic S., Gouttefangeas C., Wernet D., Hennenlotter J., Bedke J., Dietz K., Pascolo S., Kuczyk M., Rammensee H.-G., Stenzl A., Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer Prostate 2009 69 9 917 927
46. Kirkwood J. M., Lee S., Moschos S., Albertini M. R., Michalak J. C., Sander C., Whiteside T., Butterfield L. H., Weiner L., Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFIN- 2b in advanced metastatic melanoma: eastern cooperative oncology group phase II trial E1696 Clinical Cancer Research 2009 15 4 1443 1451
47. Lee P., Wang F., Kuniyoshi J., Rubio V., Stuges T., Groshen S., Gee C., Lau R., Jeffery G., Margolin K., Marty V., Weber J., Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma Journal of Clinical Oncology 2001 19 18 3836 3847
48. Slingluff C. L. Jr., Petroni G. R., Olson W. C., Smolkin M. E., Ross M. I., Haas N. B., Grosh W. W., Boisvert M. E., Kirkwood J. M., Chianese-Bullock K. A., Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-Cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial Clinical Cancer Research 2009 15 22 7036 7044
49. Rosenberg S. A., Sherry R. M., Morton K. E., Yang J. C., Topalian S. L., Royal R. E., Kammula U. S., Restifo N. P., Hughes M. S., Schwarz S. L., Ngo L. T., Mavroukakis S. A., White D. E., Altered CD8+ T-cell responses when immunizing with multiepitope peptide vaccines Journal of Immunotherapy 2006 29 2 224 231
50. Chianese-Bullock K. A., Irvin W. P., Petroni G. R., Murphy C., Smolkin M., Olson W. C., Coleman E., Boerner S. A., Nail C. J., Neese P. Y., Yuan A., Hogan K. T., Slingluff C. L. Jr., A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer Journal of Immunotherapy 2008 31 4 420 430
51. Barve M., Bender J., Senzer N., Cunningham C., Greco F. A., McCune D., Steis R., Khong H., Richards D., Stephenson J., Ganesa P., Nemunaitis J., Ishioka G., Pappen B., Nemunaitis M., Morse M., Mills B., Maples P. B., Sherman J., Nemunaitis J. J., Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer Journal of Clinical Oncology 2008 26 27 4418 4425
52. Wolff J. A., Dowty M. E., Jiao S., Repetto G., Berg R. K., Ludtke J. J., Williams P., Slautterback D. B., Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle Journal of Cell Science 1992 103 4 1249 1259
53. Ulmer J. B., Fu T.-M., Deck R. R., Friedman A., Guan L., DeWitt C., Liu X., Wang S., Liu M. A., Donnelly J. J., Caulfield M. J., Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA Journal of Virology 1998 72 7 5648 5653
54. Donnelly J. J., Wahren B., Liu M. A., DNA vaccines: progress and challenges Journal of Immunology 2005 175 2 633 639
55. Prud'homme G. J., DNA vaccination against tumors Journal of Gene Medicine 2005 7 1 3 17
56. Lowe D. B., Shearer M. H., Jumper C. A., Kennedy R. C., Towards progress on DNA vaccines for cancer Cellular and Molecular Life Sciences 2007 64 18 2391 2403
57. Shaw D. R., Strong T. V., DNA vaccines for cancer Frontiers in Bioscience 2006 11 1 1189 1198
58. Rice J., Ottensmeier C. H., Stevenson F. K., DNA vaccines: precision tools for activating effective immunity against cancer Nature Reviews Cancer 2008 8 2 108 120
59. Guermonprez P., Saveanu L., Kleijmeer M., Davoust J., Van Endert P., Amigorena S., ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells Nature 2003 425 6956 397 402
60. Stevenson F. K., Ottensmeier C. H., Johnson P., Zhu D., Buchan S. L., McCann K. J., Roddick J. S., King A. T., McNicholl F., Savelyeva N., Rice J., DNA vaccines to attack cancer Proceedings of the National Academy of Sciences of the United States of America 2004 101 supplement 2 14646 14652
61. Rowell J. F., Ruff A. L., Guarnieri F. G., Staveley-O'Carroll K., Lin X., Tang J., Thomas August J., Siliciano R. F., Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells Journal of Immunology 1995 155 4 1818 1828
62. Mateo L., Gardner J., Chen Q., Schmidt C., Down M., Elliott S. L., Pye S. J., Firat H., Lemonnier F. A., Cebon J., Suhrbier A., An HLA-A2 polyepitope vaccine for melanoma immunotherapy Journal of Immunology 1999 163 7 4058 4063
63. Ishioka G. Y., Fikes J., Hermanson G., Livingston B., Crimi C., Qin M., Del Guercio M.-F., Oseroff C., Dahlberg C., Alexander J., Chesnut R. W., Sette A., Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes Journal of Immunology 1999 162 7 3915 3925
64. Palmowski M. J., Choi E. M.-L., Hermans I. F., Gilbert S. C., Chen J.-L., Gileadi U., Salio M., Van Pel A., Man S., Bonin E., Liljestrom P., Dunbar P. R., Cerundolo V., Competition between CTL narrows the immune response induced by prime-boost vaccination protocols Journal of Immunology 2002 168 9 4391 4398
65. Velders M. P., Weijzen S., Eiben G. L., Elmishad A. G., Kloetzel P.-M., Higgins T., Ciccarelli R. B., Evans M., Man S., Smith L., Kast W. M., Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine Journal of Immunology 2001 166 9 5366 5373
66. Nussbaum A. K., Kuttler C., Hadeler K.-P., Rammensee H.-G., Schild H., PAProC: a prediction algorithm for proteasomal cleavages available on the WWW Immunogenetics 2001 53 2 87 94
67. Driscoll J., Brown M. G., Finley D., Monaco J. J., MHC-linked LMP gene products specifically alter peptidase activities of the proteasome Nature 1993 365 6443 262 264
68. Chang S.-C., Momburg F., Bhutani N., Goldberg A. L., The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a molecular ruler mechanism Proceedings of the National Academy of Sciences of the United States of America 2005 102 47 17107 17112
69. Wang Y., Guttoh D. S., Androlewicz M. J., TAP prefers to transport melanoma antigenic peptides which are longer than the optimal T-cell epitope: evidence for further processing in the endoplasmic reticulum Melanoma Research 1998 8 4 345 353
70. Momburg F., Roelse J., Hmmerling G. J., Neefjes J. J., Peptide size selection by the major histocompatibility complex-encoded peptide transporter Journal of Experimental Medicine 1994 179 5 1613 1623
71. Bergmann C. C., Yao Q., Ho C.-K., Buckwold S. L., Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes Journal of Immunology 1996 157 8 3242 3249
72. Del Val M., Schlicht H.-J., Ruppert T., Reddehase M. J., Koszinowski U. H., Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein Cell 1991 66 6 1145 1153
73. Thomson S. A., Khanna R., Gardner J., Burrows S. R., Coupar B., Moss D. J., Suhrbier A., Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design Proceedings of the National Academy of Sciences of the United States of America 1995 92 13 5845 5849
74. Qin H., Zhou C., Wang D., Ma W., Liang X., Lin C., Zhang Y., Zhang S., Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens Immunology Letters 2005 99 1 85 93
75. Qin H., Zhou C., Wang D., Ma W., Liang X., Lin C., Zhang Y., Zhang S., Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens Immunology 2006 117 3 419 430
76. Sun W., Qian H., Zhang X., Zhou C., Liang X., Wang D., Fu M., Ma W., Zhang S., Lin C., Induction of protective and therapeutic antitumour immunity using a novel tumour-associated antigen-specific DNA vaccine Immunology and Cell Biology 2006 84 5 440 447
77. Zhang X., Yu C., Zhao J., Fu L., Yi S., Liu S., Yu T., Chen W., Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice Journal of Gene Medicine 2007 9 8 715 726
78. Doan T., Herd K., Ramshaw I., Thomson S., Tindle R. W., A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour Cancer Immunology, Immunotherapy 2005 54 2 157 171
79. Kim D., Hoory T., Monie A., Ting J. P.-Y., Hung C.-F., Wu T.-C., Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun Journal of Immunology 2008 180 10 7019 7027
80. Rice J., Elliott T., Buchan S., Stevenson F. K., DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines Journal of Immunology 2001 167 3 1558 1565
81. Hung C.-F., Tsai Y.-C., He L., Wu T.-C., DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ t-cell immune responses and enhances vaccine potency Molecular Therapy 2007 15 6 1211 1219
82. Scardino A., Alimandi M., Correale P., Smith S. G., Bei R., Firat H., Cusi M. G., Faure O., Graf-Dubois S., Cencioni G., Marrocco J., Chouaib S., Lemonnier F. A., Jackson A. M., Kosmatopoulos K., A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge Cancer Research 2007 67 14 7028 7036
83. Durntez M., Lpez-Vzquez A. B., De Cerio A. L.-D., Huarte E., Casares N., Prieto J., Borrs-Cuesta F., Lasarte J. J., Sarobe P., Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes Scandinavian Journal of Immunology 2009 69 2 80 89
84. Smith S. G., Patel P. M., Porte J., Selby P. J., Jackson A. M., Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses Clinical Cancer Research 2001 7 12 4253 4261
85. Tong X. M., Zheng S. E., Bader A., Yao H. P., Wu N. P., Altmeyer P., Brockmeyer N. H., Jin J., Construction of expression vector of HTERT- HIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT European Journal of Medical Research 2008 13 1 7 14
86. Wu Y., Wan T., Zhou X., Wang B., Yang F., Li N., Chen G., Dai S., Liu S., Zhang M., Cao X., Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine Cancer Research 2005 65 11 4947 4954
87. Rosenberg S. A., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., White D. E., Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen Human Gene Therapy 2003 14 8 709 714
88. Triozzi P. L., Aldrich W., Allen K. O., Carlisle R. R., LoBuglio A. F., Conry R. M., Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse Journal of Immunotherapy 2005 28 4 382 388
89. Pavlenko M., Roos A.-K., Lundqvist A., Palmborg A., Miller A. M., Ozenci V., Bergman B., Egevad L., Hellstrm M., Kiessling R., Masucci G., Wersll P., Nilsson S., Pisa P., A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer British Journal of Cancer 2004 91 4 688 694
90. Miller A. M., zenci V., Kiessling R., Pisa P., Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer Journal of Immunotherapy 2005 28 4 389 395
91. Tagawa S. T., Lee P., Snively J., Boswell W., Ounpraseuth S., Lee S., Hickingbottom B., Smith J., Johnson D., Weber J. S., Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma Cancer 2003 98 1 144 154
92. Klencke B., Matijevic M., Urban R. G., Lathey J. L., Hedley M. L., Berry M., Thatcher J., Weinberg V., Wilson J., Darragh T., Jay N., Da Costa M., Palefsky J. M., Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101 Clinical Cancer Research 2002 8 5 1028 1037
93. Smith C. L., Dunbar P. R., Mirza F., Palmowski M. J., Shepherd D., Gilbert S. C., Coulie P., Schneider J., Hoffman E., Hawkins R., Harris A. L., Cerundolo V., Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence International Journal of Cancer 2005 113 2 259 266
94. Hama A., Benlalam H., Meslin F., Hasmim M., Carr T., Akalay I., Janji B., Berchem G., Noman M. Z., Chouaib S., Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 2010 75 1 1 8
95. Sica A., Allavena P., Mantovani A., Cancer related inflammation: the macrophage connection Cancer Letters 2008 267 2 204 215
96. Lu S., Immunogenicity of DNA vaccines in humans: it takes two to tango Human Vaccines 2008 4 6 449 452
97. Singh S. P., Mishra B. N., Prediction of MHC binding peptide using Gibbs motif sampler, weight matrix and artificial neural network Bioinformation 2008 3 4 150 155